Supplemental material
Open access
3,404
Views
4
CrossRef citations to date
0
Altmetric
Neurology
The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy
Imtiaz A. SamjooValue & Evidence Division, Marketing and Market Access, Eversana, Burlington, Canada;
, Elizabeth M. SalvoValue & Evidence Division, Marketing and Market Access, Eversana, Burlington, Canada;
, Diana TranValue & Evidence Division, Marketing and Market Access, Eversana, Burlington, Canada;
, Leslie AmassPfizer Inc., New York, NY, USA;
, Michelle StewartPfizer Inc., New York, NY, USA;
& Chris CameronValue & Evidence Division, Marketing and Market Access, Eversana, Sydney, CanadaCorrespondence[email protected]
Pages 799-808
|
Received 27 Nov 2019, Accepted 01 Feb 2020, Published online: 17 Feb 2020
Related Research Data
Familial amyloidotic polyneuropathy: current and emerging treatment options for transthyretin-mediated amyloidosis.
Source:
Informa UK Limited
The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.
Source:
Mary Ann Liebert Inc
Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
Source:
Informa UK Limited
A chain of evidence with mixed comparisons: models for multi-parameter synthesis and consistency of evidence
Source:
Wiley
A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Source:
SAGE Publications
Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.
Source:
Elsevier BV
An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
Source:
Informa UK Limited
Norfolk QOL-DN
Source:
Wiley
Online registry for mutations in hereditary amyloidosis including nomenclature recommendations.
Source:
Wiley
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
Source:
BioMed Central
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Source:
Massachusetts Medical Society
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.